Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 9.01 · 8-K

SRX Global Inc.

SRXHNYSE_AMERICANEQUITYCurrent

Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Stock Purchase Agreement On October 6, 2026, SRX Global Inc., a Delaware corporation formerly known as SRx Health Solutions, Inc. (the “Company” or “SRX”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with CERo Therapeutics Holdings, Inc., a Delaware corporation (“Holdings”).…

Filed Oct 7, 2026Accepted Oct 7, 2026, 8:05 AM EDTCIK 1471727Accession 0001493152-26-046085
Share

Company context

Current securities

Historical securities (1)

Recent company filings

  1. Regulation FD DisclosureOct 6, 2026
  2. Entry into a Material Definitive AgreementSep 9, 2026
  3. Entry into a Material Definitive AgreementSep 2, 2026
  4. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesAug 28, 2026
  5. Results of Operations and Financial ConditionAug 19, 2026

Registered securities in this filing

SRX GLOBAL INC. · 8-K · Filed 2026-10-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
SRXH
Exchange
NYSEAMER
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-10-06

Dimensions: Not supplied

Accession 000149315226046085 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement. Stock Purchase Agreement On October 6, 2026, SRX Global Inc., a Delaware corporation formerly known as SRx Health Solutions, Inc. (the “Company” or “SRX”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with CERo Therapeutics Holdings, Inc., a Delaware corporation (“Holdings”). Subject to the terms and conditions of the Purchase Agreement, the Company will acquire from Holdings all of the outstanding capital stock of CERo Therapeutics, Inc., Holdings’ wholly owned operating subsidiary (the “Subsidiary”), which acquisition is referred to herein as the “Transaction.” Upon completion of the Transaction (the “Closing”), the Subsidiary will become a wholly owned subsidiary of the Company. In connection with the signing of the Purchase Agreement, the maturity date of the Consolidated Senior Secured Promissory Note entered into on August 27, 2026 (the “Consolidated Note”) will be extended to the date that is five (5) business days following the earlier of the Closing Date or the valid termination of the Purchase Agreement pursuant to its terms. The following descriptions of the Purchase Agreement is a summary only, does not purport to be complete, and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Purchase Agreement. Consideration At Closing, the Company will (i) issue to Holdings shares of the Company’s common stock determined by dividing $1,000,000.00 by the lower of (a) the closing price of the Company’s common stock on the NYSE American on the trading day immediately preceding the date of the Purchase Agreement and (b) the 20-day volume-weighted average price (“VWAP”) of the Company’s common stock on the NYSE American ending on such date, subject to adjustment for specified changes in the Company’s capital structure; (ii) forgive, cancel and discharge all obligations under the Consolidated Note (in the original principal amount of up to $11,666,108.77) and related loan documents (which as of the date of this Report, has an outstanding principal balance of $8,249,643.77), plus accrued and unpaid interest, fees and expenses; and (iii) assume the liabilities specified in the Purchase Agreement and related assumption agreement in the amount of approximately $1,562,000, with the Company agreeing to defend, indemnify and hold harmless Holdings and its past, present and future officers and directors from and against any and all claims, liabilities and expenses arising out of or resulting from the assumed liabilities. The debt discharge will be accompanied by termination of the related Pledge Agreement, Security Agreement and Company Guaranty and releases of liens securing the obligations represented by the Consolidated Note on the Subsidiary’s stock and assets. Go-Shop and Superior Proposals The Purchase Agreement provides for a 30-day go-shop period beginning on the signing date and ending thirty (30) days from the signing date (the “Go-Shop Period”). During this period, Holdings and its representatives may actively solicit, initiate, facilitate and encourage alternative acquisition proposals and provide nonpublic information under acceptable confidentiality agreements. Holdings has retained Joseph Gunnar & Co., LLC to conduct the go-shop process. Holdings is required to notify the Company within 24 hours after receipt of an acquisition proposal during the Go-Shop Period, identify the bidder and summarize the material terms, and keep the Company reasonably informed of material developments. If Holdings receives a Superior Proposal before the Go-Shop Period expires, the Purchase Agreement provides up to 45 additional days after the go-shop end date to negotiate such proposal and execute a definitive agreement. A “Superior Proposal” must, among other requirements, be a bona fide written proposal that the Holdings board of directors determines in good faith, after consultation with its financial advisor and outside counsel, is more favorable to Holdings than the Transaction, taking into account any revisions proposed by the Company. The proposal must not be subject to third-party financing and must require consummation no later than March 15, 2027. A qualifying alternative acquisition proposal must also contemplate full repayment of Holdings’ obligations under the Consolidated Note and related security documents, release of the related liens and payment of the applicable termination fee to the Company. 2 After the Go-Shop Period, the Purchase Agreement restricts further solicitation, information sharing and negotiations by Holdings, subject to negotiation of any Superior Proposal received during the Go-Shop Period and a fiduciary exception for qualifying unsolicited written proposals. Before terminating the Purchase Agreement to enter into an agreement for a Superior Proposal, Holdings must comply with the applicable procedures, including providing the Company with at least three business days’ prior written notice and, if requested, engaging in good-faith negotiations regarding revisions offered by the Company. A material amendment to the competing proposal requires a new two-business-day notice period. The Holdings board must determine that the competing proposal remains superior after considering the Company’s proposed revisions, and Holdings must pay the applicable termination fee in connection with such termination. There can be no assurance that the go-shop process will not result in a Superior Proposal or that the Transaction will be completed. Termination rights and reciprocal termination fees The Purchase Agreement may be terminated in specified circumstances, including by mutual agreement, upon a final legal prohibition, for specified uncured breaches, or if Closing has not occurred by the applicable outside date. Holdings may also terminate to enter into an agreement for a Superior Proposal in compliance with the go-shop procedures, and the Buyer may terminate for a breach of the go-shop provisions or an adverse change in the Holdings board’s recommendation. Holdings is required to pay a $750,000 termination fee in the circumstances specified in the Purchase Agreement, including if the Purchase Agreement is terminated in connection with Holdings’ acceptance of a Superior Proposal or by the Buyer following certain breaches of the go-shop provisions or an adverse recommendation change. The fee may also become payable following certain terminations relating to the outside date or a breach by Holdings if a qualifying acquisition proposal was outstanding and Holdings enters into an agreement for, or completes, an alternative acquisition within 12 months following termination. SRX may also be required to pay Holdings $750,000 if the Purchase Agreement is terminated in specified circumstances involving SRX’s failure to fund or deliver the required consideration after the conditions to the Buyer’s obligations to consummate the Transaction have been satisfied, subject to the applicable termination and cure provisions of the Purchase Agreement. The Purchase Agreement also provides for reimbursement of up to $100,000 of the Buyer’s reasonable, documented transaction expenses following certain Company-breach terminations, with amounts paid credited against a subsequently payable Company termination fee. Subject to the Purchase Agreement, Holdings may elect specific performance instead of the reverse termination fee, and fraud and willful-breach remedies are preserved. Closing Conditions The Closing of the Transaction is conditioned upon the Company’s acquisition of the shares of Holdings’ Series C, Series D and Series E preferred stock. The Closing is also conditioned upon the holders of Holdings’ Series A preferred stock holding the requisite percentage or amount of such preferred stock providing the applicable waivers or consents and/or converting their Series A preferred stock into Holdings common stock, in each case as specified in the transaction documents. In evaluating arrangements to satisfy the Series A preferred stock closing condition, discussions have occurred regarding potential minority equity participation in a post-closing acquisition entity; any such arrangements, if finalized, remain subject to definitive documentation, mutual agreement with the applicable preferred holders and review by the Special Committee. 3 Completion of the Transaction remains subject to the satisfaction or permitted waiver of the applicable closing conditions, including specified consents, the accuracy of representations and warranties, material compliance with covenants, the absence of specified material adverse effects, the preferred stock arrangements described above and delivery of the required transaction documents. Holdings’ conditions include the Company’s funding of the required advances and delivery of the registration rights agreement providing for registration of the resale of the Company’s shares issued to Holdings or their subsequent distribution to Holdings’ stockholders, and requiring the Company to use commercially reasonable efforts to obtain and maintain the effectiveness of the applicable registration statements, subject to the terms of that agreement. The Company’s obligations are not subject to a financing condition. The Purchase Agreement contemplates Closing on the first business day following the end of the Go-Shop Period on which the closing conditions are satisfied or waived, unless the parties agree otherwise in writing, subject to the applicable Superior Proposal provisions. The Purchase Agreement contains representations, warranties and covenants, including restrictions on the Subsidiary’s conduct before Closing. It contemplates employment agreements with certain key employees, 180-day lock-up agreements for specified recipients of consideration shares and registration rights relating to the Company’s shares. Pursuant to the Purchase Agreement, Holdings may obtain, at its cost and expense, a prepaid “tail” directors’ and officers’ liability insurance policy covering current and former directors and officers of Holdings and the Subsidiary, funded in part from funds previously set aside by Holdings for such purpose. In addition, the Company has unconditionally guaranteed all indemnification, advancement and exculpation obligations of the Subsidiary, and effective upon the Closing, the Company, on behalf of itself, its affiliates and the acquired Subsidiary, has agreed to deliver a comprehensive mutual release extinguishing all pre-closing claims and liabilities against Holdings and its current and former officers, directors, employees and advisors, with such individuals designated as express third-party beneficiaries entitled to enforce such protections directly. The foregoing summary is qualified in its entirety by reference to the Purchase Agreement, filed as Exhibit 10.1 to this report and incorporated herein by reference. Forward looking statements This report contains forward-looking statements concerning the proposed Transaction, the go-shop process, potential alternative proposals, anticipated funding and debt relief, the allocation of liabilities, preferred stock arrangements and the timing of Closing. These statements reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Those risks include failure to complete either the Transaction or an alternative transaction; inability to obtain required consents or creditor settlements; financing and liquidity constraints; debt maturity, default and enforcement risks; changes in the value or liquidity of SRX shares; and disruption to the Subsidiary’s operations, personnel, development activities and business relationships. Additional risks are described in Holdings’ filings with the SEC. Holdings undertakes no obligation to update these statements except as required by law.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.